Repligen Corporation (NASDAQ: RGEN) reported today top-line results from a Phase 3 clinical trial to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE